ABVC BioPharma, Inc. (ABVC) AI Stock Analysis
ABVC AI stock analysis summary
AI ResearchABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company developing therapeutic candidates and medical devices. Over the trailing twelve months, the company generated $797,916 in revenue with an EPS of -$0.30. Its balance sheet shows $94,364 in cash and short-term investments alongside total debt of $1.8M as of June 30, 2026.
- Market cap
- $24.5M
- Revenue (TTM)
- $797,916
- P/E
- —
- 1Y return
- -68.6% S&P 500 16.8%
- Avg. target
- $2.02 120.0% vs last close
Bull case
- Quarterly revenue grew 104.5% year-over-year in the latest quarter ending June 30, 2026.
- Gross margin reached 100.0% in FY2025 on annual revenue of $795,950.
- The analyst mean price target of $2.02 represents an upside of 120.0% relative to the close of $0.92.
Bear case
- The company held only $94,364 in cash and short-term investments against a current ratio of 0.07 as of June 30, 2026.
- Cash burn continues with an operating cash flow of -$3.0M and free cash flow of -$3.0M in FY2025.
- Shareholders experienced significant dilution, with the 5-year share count expanding by 903.5%.
What ABVC BioPharma does
ABVC BioPharma, Inc. is a Fremont, California-based clinical-stage biopharmaceutical firm originally established as a subsidiary of YuanGene Corporation. The company focuses on developing drugs and medical devices for unmet medical needs in the United States. Its pipeline features ABV-1501, which is in Phase I/II clinical trials for triple negative breast cancer. It has completed Phase II trials for ABV-1504 in major depressive disorders and is advancing ABV-1505 in Phase II trials for attention deficit hyperactivity disorder (ADHD). It also completed Phase I trials for ABV-1703 in pancreatic cancer and ABV-1702 for myelodysplastic syndromes, supported by partnerships with Rgene Corporation, BioHopeKing Corporation, and BioFirst Corporation.
Growth and profitability
ABVC saw revenue fluctuate significantly over recent years, moving from $355,797 in FY2021 to $969,783 in FY2022, followed by a decline to $152,430 in FY2023. Revenue subsequently rebounded to $509,589 in FY2024 and rose 56.2% to $795,950 in FY2025, yielding a 5-year revenue CAGR of 10.5% from FY2020 to FY2025. Gross margin reached 100.0% in FY2025, while operating margin remained negative at -898.5% and net income finished at -$7.9M. For the latest quarter ended June 30, 2026, quarterly revenue grew 104.5% year-over-year, bringing trailing twelve-month revenue to $797,916.
Balance sheet and cash flow
As of June 30, 2026, ABVC BioPharma held $94,364 in cash and short-term investments against total debt of $1.8M, resulting in net debt of $1.7M. Total assets stood at $19.4M, shareholders' equity was $10.3M, and the current ratio was 0.07. Debt-to-equity was 0.17. In FY2025, operating cash flow was -$3.0M, free cash flow was -$3.0M, and capital expenditures were $5,791. Over the last five years, the company's share count increased by 903.5%.
Valuation and performance
ABVC BioPharma traded at a market capitalization of $24.5M and an enterprise value of $32.9M as of October 16, 2026. The stock trades at a price-to-sales multiple of 111.7x and an EV-to-revenue multiple of 184.6x, compared to a price-to-sales ratio of 4.1x for the median of its US-listed Healthcare peers. Its price-to-book ratio is 3.0x. Over the past year, the stock fell 68.6%, compared to a 16.8% gain for the S&P 500 (SPY), and its 5-year return is -96.6% compared to 83.0% for SPY.
What analysts expect
Wall Street analysts set a mean price target of $2.02 for ABVC BioPharma, representing a 120.0% premium over its last close of $0.92 on October 16, 2026. The company has beat EPS estimates in 1 of the last 4 quarters. The next earnings date is scheduled for October 30, 2026.
Key risks and what to watch
- The current ratio stands at 0.07 with $94,364 in cash, presenting liquidity challenges given annual free cash flow of -$3.0M in FY2025.
- Share count grew 903.5% over five years, indicating potential for continued equity dilution to finance ongoing trials.
- The stock is trading 30.2% below its 200-day average following a 1-year decline of 68.6%.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ABVC AI stock analysis
This page is an AI-written research summary of ABVC BioPharma, Inc. (ABVC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ABVC income statement, ABVC balance sheet, ABVC key metrics, ABVC chart. See the ABVC stock overview for the latest quote and news.
ABVC AI stock analysis FAQ
What is ABVC BioPharma's current cash and debt position?
As of June 30, 2026, ABVC BioPharma held $94,364 in cash and short-term investments, with total debt of $1.8M and net debt of $1.7M.
Does ABVC BioPharma pay a dividend?
No, ABVC BioPharma does not pay a dividend.
What is the consensus analyst target for ABVC?
The mean analyst price target is $2.02, which is 120.0% above the last close price of $0.92 on October 16, 2026.
When is the next earnings release for ABVC BioPharma?
The next scheduled earnings date for ABVC BioPharma is October 30, 2026.